Allurion Technologies Inc ALUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALUR is a good fit for your portfolio.
News
-
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey
-
Allurion Announces Preliminary First Quarter 2024 Results
-
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
-
Allurion Expands Virtual Care Suite to the United States
-
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
-
Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
-
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
-
Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024
Trading Information
- Previous Close Price
- $1.96
- Day Range
- $1.90–2.04
- 52-Week Range
- $1.56–9.00
- Bid/Ask
- $1.81 / $2.31
- Market Cap
- $92.96 Mil
- Volume/Avg
- 41,061 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.30
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- 24
- Website
- https://www.allurion.com
Valuation
|
Metric
|
ALUR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.30 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALUR
|
|---|---|
Quick Ratio | 0.86 |
Current Ratio | 0.99 |
Interest Coverage | −6.60 |
Quick Ratio
ALUR
Profitability
|
Metric
|
ALUR
|
|---|---|
Return on Assets (Normalized) | −115.86% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ALUR
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Wqmwmgz | Msfsw | $182.6 Bil | |
SYK
| Stryker Corp | Gddsjgwbz | Thmm | $123.6 Bil | |
MDT
| Medtronic PLC | Nvdvhjtm | Njbqgx | $108.3 Bil | |
BSX
| Boston Scientific Corp | Xgwdwffs | Rgsxrmy | $107.0 Bil | |
EW
| Edwards Lifesciences Corp | Qcxcsvvxp | Yrwpqj | $51.0 Bil | |
DXCM
| DexCom Inc | Ttrznwzrp | Msx | $50.3 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Fsjbxrcz | Lnjf | $24.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Xpcvvmv | Qkfmwb | $24.3 Bil | |
ALGN
| Align Technology Inc | Nzzkbwtsj | Whvrth | $20.5 Bil | |
PODD
| Insulet Corp | Fmhsfppdgt | Mtwygh | $12.4 Bil |